Action Medivir Ab - 0GP7

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

41,70

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

41,70 Plage de 52 semaines 41,70

Cap du marché

4,394B

Clôture Veille

41,70

Ouverture

Dernière Transaction

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

0,00

Actions en circulation

105 371 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-49,19

Bénéfice par action (BPA)

-0,85

Chiffre d'affairess

7,66M

Bénéfice net

-89,32M

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Diversified

Site Web

www.medivir.se

Siège social

Huddinge, Swe

Fondé

1992

Medivir Ab est coté dans le secteur Pharmaceutical Preparations de la London Stock Exchange avec le ticker 0GP7. Le dernier cours de clôture d'Medivir Ab était de SEK41,70. Au cours de la dernière année, les actions de Medivir Ab ont été négociées dans une fourchette de prix de SEK 41,70 à SEK 41,70.

Medivir Ab compte actuellement 105 371 000 actions en circulation. La capitalisation boursière d'Medivir Ab est de SEK4,39 milliard. Medivir Ab a un ratio cours/bénéfice (ratio PE) de -49.19.

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox PR Newswire STOCKHOLM, Jan. 15, 2024 STOCKHOLM, Jan. 15, 2024...

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study PR Newswire STOCKHOLM, Jan. 4, 2024 STOCKHOLM, Jan. 4, 2024...

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan PR Newswire STOCKHOLM, Dec. 19, 2023 Sustained disease control...

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval PR Newswire STOCKHOLM, Dec. 13, 2023 STOCKHOLM...

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway PR Newswire STOCKHOLM, Dec. 6, 2023 STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB...

Medivir to present at the Carlsquare Equity Research Investor Day

Medivir to present at the Carlsquare Equity Research Investor Day PR Newswire STOCKHOLM, Dec. 6, 2023 STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical...

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Bulletin from Extraordinary General Meeting in Medivir AB (publ) PR Newswire STOCKHOLM, Dec. 1, 2023 STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the...

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC PR Newswire STOCKHOLM, Nov. 27, 2023 STOCKHOLM, Nov. 27...

Medivir to present at the Redeye Life Science Day

Medivir to present at the Redeye Life Science Day PR Newswire STOCKHOLM, Nov. 22, 2023 STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company...

Medivir to present at the Erik Penser Bank Company Event

Medivir to present at the Erik Penser Bank Company Event PR Newswire STOCKHOLM, Nov. 21, 2023 STOCKHOLM, Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical...

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	41.7	41.7	41.7	0	0	DE
4	41.7	41.7	41.7	0	0	DE
12	41.7	41.7	41.7	0	0	DE
26	41.7	41.7	41.7	0	0	DE
52	41.7	41.7	41.7	46	41.7	DE
156	41.7	41.7	41.7	48	41.7	DE
260	41.7	41.7	41.7	253	41.7	DE

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
BLUBlue Star Capital Plc	0,025p (42,86%)	98,74M
SCGLSealand Capital Galaxy Limited	0,415p (38,33%)	13,62M
SCESurface Transforms Plc	0,34p (30,77%)	108,26M
COBRCobra Resources Plc	1,25p (25,00%)	10,33M
IESInvinity Energy Systems Plc	14,50p (23,40%)	3,28M
UOGUnited Oil & Gas Plc	0,125p (-34,21%)	116,68M
SYSSysgroup Plc	21,50p (-24,56%)	512,48k
KEFIKefi Gold And Copper Plc	0,522p (-19,94%)	326,76M
GENLGenel Energy Plc	72,40p (-17,82%)	1,9M
KZGKazera Global Plc	1,075p (-14,00%)	1,25M
ORCPOracle Power Plc	0,0585p (2,63%)	2,12B
NTVONativo Resources Plc	0,0023p (-8,00%)	575,78M
KEFIKefi Gold And Copper Plc	0,522p (-19,94%)	326,76M
TRPTower Resources Plc	0,03p (1,69%)	165,29M
CLONClontarf Energy Plc	0,0335p (-10,67%)	118,1M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medivir Ab (0GP7)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Medivir Ab

0GP7 Dernières nouvelles

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir to present at the Carlsquare Equity Research Investor Day

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir to present at the Redeye Life Science Day

Medivir to present at the Erik Penser Bank Company Event

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir to present at the Carlsquare Equity Research Investor Day

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medivir Ab (0GP7) Cours

Medivir Ab (0GP7)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Medivir Ab

0GP7 Dernières nouvelles

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application